Is Viatris Inc (VTRS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 90.1% / 30% | 9.3% / 30% | 20.5% / 30% | 24.11% / 5% | ✗ NOT HALAL |
| DJIM | 90.1% / 33% | 9.3% / 33% | 20.5% / 33% | 24.11% / 5% | ✗ NOT HALAL |
| MSCI | 39.5% / 33% | 4.1% / 33% | 9.0% / 33% | 24.11% / 5% | ✗ NOT HALAL |
| S&P | 90.1% / 33% | 9.3% / 33% | 20.5% / 33% | 24.11% / 5% | ✗ NOT HALAL |
| FTSE | 39.5% / 33% | 4.1% / 33% | 9.0% / 50% | 24.11% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 39.5% | |
| Operating Margin | 7.8% | |
| Net Margin | -24.6% | |
| Return on Equity (ROE) | -21.1% | |
| Return on Assets (ROA) | 2.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $2.3B |
| Free Cash Flow | $1.9B |
| Total Debt | $14.7B |
| Debt-to-Equity | 99.9 |
| Current Ratio | 1.4 |
| Total Assets | $37.2B |
Price & Trading
| Last Close | $13.37 |
| 50-Day MA | $14.26 |
| 200-Day MA | $11.28 |
| Avg Volume | 10.3M |
| Beta | 0.8 |
|
52-Week Range
$6.85
| |
About Viatris Inc (VTRS)
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Viatris Inc (VTRS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Viatris Inc is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Viatris Inc's debt ratio?
Viatris Inc's debt ratio is 90.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 39.5%.
What are Viatris Inc's key financial metrics?
Viatris Inc has a market capitalization of $15.0B, and revenue of $14.3B. The company maintains a gross margin of 39.5% and a net margin of -24.6%. Return on equity stands at -21.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.